Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : sciclone pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: JEB who wrote (866)	8/19/2001 1:50:18 AM
From: Captain Jack	Read Replies (1) \| Respond to of 1137

Do you not think if mgmt was able to schmooze wall street very effectively they should do better. A bio co that has rev & R&D?? Seems the best of both worlds...... at least they can get the pr into the services,,, just no one pays attn any more/////

To: JEB who wrote (866)	8/19/2001 8:19:24 PM
From: Oak Tree	Read Replies (1) \| Respond to of 1137

There are a lot of companies developing their own ant-EGFR drug. Needless to say, this drug is not aimed at killing cancer cells. They, at best, simply hope it will grow slower. They also hope it will make the chemo work a bit better. Chemotherapy is not judged successful if it doesn't shrink cancer. They are not even expecting this to shrink cancer. vis - this drug (these drugs) are less good than chemotherapy. Its hard to understand all the hype around these drugs. Patience should yield a nice profit to the careful shorter of IMCL.